{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.22","upperLimit":"16.63","value":"15.21"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"Progression free survival is the time between the date of initiation of therapy to progressive disease (PD) or death from any cause, whichever occurs first. See outcome #4 for a definition of PD.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bendamustine in escalating doses of 50, 70 or 90 mg/m\\^2 as combination therapy with bortezomib at 1.0 mg/m\\^2/dose administered for up to eight 28 day cycles. Participants whose disease has not progressed at the end of the eight cycles will be followed until disease progression or death.","id":"OG000","title":"Bendamustine and Bortezomib - Overall"}],"paramType":"MEDIAN","populationDescription":"Safety population","reportingStatus":"POSTED","timeFrame":"up to 23 months","title":"Kaplan-Meier Estimate for Progression-Free Survival","type":"SECONDARY","unitOfMeasure":"months"}